MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studies how well Akt inhibitor MK2206 works in treating patients with
stage I-III breast cancer that can be removed by surgery. Akt inhibitor MK2206 may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.